Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00419094 · ClinicalTrials.gov registry record · Phase 3
Conversion to Monotherapy Study With Keppra XR for Partial Seizures
A Phase 3 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 228
- Enrollment target
NCT00419094 is a Phase 3 study that has completed, run by UCB Pharma. The registered enrollment target is 228 participants.
The verdict
NCT00419094, a Phase 3 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 228 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the efficacy of two doses of Keppra XR compared with a historical control as the placebo, in the monotherapy treatment of partial onset seizures.
Interventions
- DRUG Keppra XR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2007-08 |
| Est. Completion | 2009-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00419094
The ClinicalTrials.gov registry entry for NCT00419094 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 228 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Keppra XR is the first listed.
NCT00419094 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00419094 about?
NCT00419094 is a clinical study titled "Conversion to Monotherapy Study With Keppra XR for Partial Seizures". The primary objective of this study is to assess the efficacy of two doses of Keppra XR compared with a historical control as the placebo, in the monotherapy treatment of partial onset seizures.
What is the current status of trial NCT00419094?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 228 participants. The study started on 2007-08. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00419094?
The interventions under investigation include: Keppra XR (DRUG).
Who is sponsoring clinical trial NCT00419094?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.